Tofacitinib: Difference between revisions
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{CMG}} ==Overview== Tofacitinib <ref name="FORBES">{{cite news|url=http://blogs.forbes.com/matthewherper/2011/03/02/why-pfizers-biggest-experimental-drug-got-a-nam...") |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
Tofacitinib | Tofacitinib is a [[pharmaceutical drug|drug]] [[drug discovery|discovered]] and [[drug development|developed]] by [[Pfizer]]. It is currently approved for the treatment of [[rheumatoid arthritis]] (RA) in the United States and is being studied for treatment of [[psoriasis]], [[inflammatory bowel disease]], and other immunological diseases, as well as for the prevention of [[organ transplant]] rejection. | ||
==Mechanism== | ==Mechanism== | ||
It is an [[Janus kinase inhibitor|inhibitor]] of the enzyme [[janus kinase 3]] (JAK3), which means that it interferes with the [[JAK-STAT signaling pathway]], which transmits extracellular information into the cell nucleus, influencing [[DNA transcription]].<ref>{{ | It is an [[Janus kinase inhibitor|inhibitor]] of the enzyme [[janus kinase 3]] (JAK3), which means that it interferes with the [[JAK-STAT signaling pathway]], which transmits extracellular information into the cell nucleus, influencing [[DNA transcription]].<ref name="pmid21171673">{{cite journal| author=| title=Tofacitinib. | journal=Drugs R D | year= 2010 | volume= 10 | issue= 4 | pages= 271-84 | pmid=21171673 | doi=10.2165/11588080-000000000-00000 | pmc=PMC3585773 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21171673 }} </ref> | ||
Recently it has been shown in a murine model of established arthritis that tofacitinib rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing [[STAT1]]-dependent genes in joint tissue. This efficacy in this disease model correlated with the inhibition of both [[JAK1]] and 3 signaling pathways, suggesting that tofacitinib may exert therapeutic benefit via pathways that are not exclusive to inhibition of JAK3.<ref>{{ | Recently it has been shown in a murine model of established arthritis that tofacitinib rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing [[STAT1]]-dependent genes in joint tissue. This efficacy in this disease model correlated with the inhibition of both [[JAK1]] and 3 signaling pathways, suggesting that tofacitinib may exert therapeutic benefit via pathways that are not exclusive to inhibition of JAK3.<ref name="pmid21383241">{{cite journal| author=Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW et al.| title=Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). | journal=J Immunol | year= 2011 | volume= 186 | issue= 7 | pages= 4234-43 | pmid=21383241 | doi=10.4049/jimmunol.1003668 | pmc=PMC3108067 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21383241 }} </ref> | ||
==Research History== | ==Research History== | ||
The potential significance of JAK3 inhibition was first discovered in the laboratory of [[John O'Shea (biologist)|John O'Shea]], an [[immunologist]] at the [[National Institute of Arthritis and Musculoskeletal and Skin Diseases]] of the [[National Institutes of Health]] (NIH). | The potential significance of JAK3 inhibition was first discovered in the laboratory of [[John O'Shea (biologist)|John O'Shea]], an [[immunologist]] at the [[National Institute of Arthritis and Musculoskeletal and Skin Diseases]] of the [[National Institutes of Health]] (NIH). In 1994, Pfizer was approached by the NIH to form a public-private partnership in order to evaluate and bring to market experimental compounds based on this research. Pfizer initially declined the partnership but agreed in 1996, after the elimination of an NIH policy dictating that the market price of a product resulting from such a partnership would need to be commensurate with the investment of public taxpayer revenue and the "health and safety needs of the public." The [[drug discovery]], [[preclinical development]], and [[clinical development]] of tofacitinib took place exclusively at Pfizer.<ref name="pmid23302910">{{cite journal| author=Garber K| title=Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. | journal=Nat Biotechnol | year= 2013 | volume= 31 | issue= 1 | pages= 3-4 | pmid=23302910 | doi=10.1038/nbt0113-3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23302910 }} </ref> | ||
In November 2012, the U.S. [[Food and Drug Administration]] (FDA) approved tofacitinib for treatment of rheumatoid arthritis. Once on the market, rheumatologists complained that the $2,055 a month wholesale price was too expensive, though the price is 7% less than related treatments.<ref name=Garber/> | In November 2012, the U.S. [[Food and Drug Administration]] (FDA) approved tofacitinib for treatment of rheumatoid arthritis. Once on the market, rheumatologists complained that the $2,055 a month wholesale price was too expensive, though the price is 7% less than related treatments.<ref name="pmid23302910">{{cite journal| author=Garber K| title=Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. | journal=Nat Biotechnol | year= 2013 | volume= 31 | issue= 1 | pages= 3-4 | pmid=23302910 | doi=10.1038/nbt0113-3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23302910 }} </ref> | ||
===Clinical Trials=== | ===Clinical Trials=== | ||
| Line 19: | Line 19: | ||
[[Phase II clinical trial]]s tested the drug in RA patients that had not responded to [[DMARD]] therapy. In a tofacitinib monotherapy study, the [[ACR score for rheumatoid arthritis|ACR score]] improved by at least 20% (ACR-20) in 67% of patients versus 25% who received [[placebo]]; and a study that combined the drug with [[methotrexate]] achieved ACR-20 in 59% of patients versus 35% who received methotrexate alone. In a psoriasis study, the [[Psoriasis Area and Severity Index|PASI]] score improved by at at least 75% in between 25 and 67% of patients, depending on the dose, versus 2% in the placebo group.<ref name="EULAR" /> | [[Phase II clinical trial]]s tested the drug in RA patients that had not responded to [[DMARD]] therapy. In a tofacitinib monotherapy study, the [[ACR score for rheumatoid arthritis|ACR score]] improved by at least 20% (ACR-20) in 67% of patients versus 25% who received [[placebo]]; and a study that combined the drug with [[methotrexate]] achieved ACR-20 in 59% of patients versus 35% who received methotrexate alone. In a psoriasis study, the [[Psoriasis Area and Severity Index|PASI]] score improved by at at least 75% in between 25 and 67% of patients, depending on the dose, versus 2% in the placebo group.<ref name="EULAR" /> | ||
The most important side effects in Phase II studies were increased [[blood cholesterol]] levels (12 to 25 mg/dl [[Low density lipoprotein|LDL]] and 8 to 10 mg/dl [[High density lipoprotein|HDL]] at medium dosage levels) and [[neutropenia]]. | The most important side effects in Phase II studies were increased [[blood cholesterol]] levels (12 to 25 mg/dl [[Low density lipoprotein|LDL]] and 8 to 10 mg/dl [[High density lipoprotein|HDL]] at medium dosage levels) and [[neutropenia]]. Phase III trials testing the drug in rheumatoid arthritis started in 2007 and are scheduled to run until January 2015. | ||
In April 2011, four patients died after beginning clinical trials with tofacitinib. According to Pfizer, only one of the four deaths was related to tofacitinib. | In April 2011, four patients died after beginning clinical trials with tofacitinib. According to Pfizer, only one of the four deaths was related to tofacitinib. | ||
By April 2011, three phase III trials for RA had reported positive results. | By April 2011, three phase III trials for RA had reported positive results. | ||
In November 2012, the U.S. FDA approved tofacitinib "to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate." A [[boxed warning]] that goes along with this approval warns patients that they are at higher risk of opportunistic infections, tuberculosis, cancers and lymphoma. | In November 2012, the U.S. FDA approved tofacitinib "to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate." A [[boxed warning]] that goes along with this approval warns patients that they are at higher risk of opportunistic infections, tuberculosis, cancers and lymphoma. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 19:54, 19 July 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Tofacitinib is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection.
Mechanism
It is an inhibitor of the enzyme janus kinase 3 (JAK3), which means that it interferes with the JAK-STAT signaling pathway, which transmits extracellular information into the cell nucleus, influencing DNA transcription.[1]
Recently it has been shown in a murine model of established arthritis that tofacitinib rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue. This efficacy in this disease model correlated with the inhibition of both JAK1 and 3 signaling pathways, suggesting that tofacitinib may exert therapeutic benefit via pathways that are not exclusive to inhibition of JAK3.[2]
Research History
The potential significance of JAK3 inhibition was first discovered in the laboratory of John O'Shea, an immunologist at the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH). In 1994, Pfizer was approached by the NIH to form a public-private partnership in order to evaluate and bring to market experimental compounds based on this research. Pfizer initially declined the partnership but agreed in 1996, after the elimination of an NIH policy dictating that the market price of a product resulting from such a partnership would need to be commensurate with the investment of public taxpayer revenue and the "health and safety needs of the public." The drug discovery, preclinical development, and clinical development of tofacitinib took place exclusively at Pfizer.[3]
In November 2012, the U.S. Food and Drug Administration (FDA) approved tofacitinib for treatment of rheumatoid arthritis. Once on the market, rheumatologists complained that the $2,055 a month wholesale price was too expensive, though the price is 7% less than related treatments.[3]
Clinical Trials
Rheumatoid Arthritis
Phase II clinical trials tested the drug in RA patients that had not responded to DMARD therapy. In a tofacitinib monotherapy study, the ACR score improved by at least 20% (ACR-20) in 67% of patients versus 25% who received placebo; and a study that combined the drug with methotrexate achieved ACR-20 in 59% of patients versus 35% who received methotrexate alone. In a psoriasis study, the PASI score improved by at at least 75% in between 25 and 67% of patients, depending on the dose, versus 2% in the placebo group.[4]
The most important side effects in Phase II studies were increased blood cholesterol levels (12 to 25 mg/dl LDL and 8 to 10 mg/dl HDL at medium dosage levels) and neutropenia. Phase III trials testing the drug in rheumatoid arthritis started in 2007 and are scheduled to run until January 2015.
In April 2011, four patients died after beginning clinical trials with tofacitinib. According to Pfizer, only one of the four deaths was related to tofacitinib.
By April 2011, three phase III trials for RA had reported positive results.
In November 2012, the U.S. FDA approved tofacitinib "to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate." A boxed warning that goes along with this approval warns patients that they are at higher risk of opportunistic infections, tuberculosis, cancers and lymphoma.
References
- ↑ "Tofacitinib". Drugs R D. 10 (4): 271–84. 2010. doi:10.2165/11588080-000000000-00000. PMC 3585773. PMID 21171673.
- ↑ Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW; et al. (2011). "Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)". J Immunol. 186 (7): 4234–43. doi:10.4049/jimmunol.1003668. PMC 3108067. PMID 21383241.
- ↑ 3.0 3.1 Garber K (2013). "Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market". Nat Biotechnol. 31 (1): 3–4. doi:10.1038/nbt0113-3. PMID 23302910.
- ↑